
M Ventures
Merck KGaA's corporate venture Arm; joined T-Therapeutics' $133m Series B in November 2026.
Last refreshed: 14 November 2026 · Appears in 1 active topic
What does Germany's Merck gain from a stake in a Cambridge spinout?
Timeline for M Ventures
Joined T-Therapeutics' Series B
UK Startups and Innovation: T-Therapeutics raises $133m in Series BBackground
M Ventures, the corporate venture Arm of the German group Merck KGaA, joined T-Therapeutics' $133m Series B on 5 November 2026 as a new investor. Advent Life Sciences and the British Business Bank co-led the round, and Eli Lilly, Johnson & Johnson Innovation and Samsara BioCapital also joined.
M Ventures is based in Amsterdam and invests in healthcare, life Science and electronics companies for its parent, which is based in Darmstadt. It has no link to the American drugmaker Merck & Co.
The stake gives Merck KGaA an early view of T-cell receptor bispecifics, a class of drug that can reach proteins inside diseased cells.
Who owns M Ventures?
Which UK biotechs has M Ventures invested in?
Where is M Ventures based?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.